| __timestamp | Taro Pharmaceutical Industries Ltd. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 55430000 | 581800000 |
| Thursday, January 1, 2015 | 65510000 | 671900000 |
| Friday, January 1, 2016 | 71160000 | 876700000 |
| Sunday, January 1, 2017 | 70644000 | 857900000 |
| Monday, January 1, 2018 | 70418000 | 822200000 |
| Tuesday, January 1, 2019 | 63238000 | 778200000 |
| Wednesday, January 1, 2020 | 59777000 | 512600000 |
| Friday, January 1, 2021 | 60152000 | 681000000 |
| Saturday, January 1, 2022 | 54540000 | 662200000 |
| Sunday, January 1, 2023 | 52243000 | 910700000 |
| Monday, January 1, 2024 | 64536000 |
Cracking the code
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Viatris Inc. and Taro Pharmaceutical Industries Ltd. have shown contrasting trends in their R&D investments. From 2014 to 2023, Viatris consistently outspent Taro, with its R&D expenses peaking in 2023 at nearly 910% more than Taro's. This significant investment underscores Viatris's commitment to innovation, despite a dip in 2020. Meanwhile, Taro's R&D spending remained relatively stable, with a slight decline in recent years, reflecting a more conservative approach. The data reveals a strategic divergence: Viatris is aggressively investing in future growth, while Taro maintains a steady course. As the pharmaceutical landscape evolves, these spending patterns may shape the competitive dynamics between these two industry players.
Comparing Innovation Spending: Gilead Sciences, Inc. and Viatris Inc.
R&D Insights: How Vertex Pharmaceuticals Incorporated and Viatris Inc. Allocate Funds
Research and Development Investment: Takeda Pharmaceutical Company Limited vs Viatris Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Insmed Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
Viatris Inc. or ImmunityBio, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Viatris Inc. and HUTCHMED (China) Limited
Viatris Inc. or MannKind Corporation: Who Invests More in Innovation?
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
R&D Insights: How Veracyte, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds